Proteome Analysis of Aflibercept Intervention in Experimental Central Retinal Vein Occlusion

• Published in: Molecules (Basel, Switzerland) Vol. 27; no. 11; p. 3360
• Main Authors: Cehofski, Lasse Jørgensen, Kruse, Anders, Alsing, Alexander Nørgaard, Sejergaard, Benn Falch, Nielsen, Jonas Ellegaard, Schlosser, Anders, Sorensen, Grith Lykke, Grauslund, Jakob, Honoré, Bent, Vorum, Henrik
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 24-05-2022; MDPI
• Subjects: aflibercept; Animals; Argon lasers; Edema; Epithelium; Eye; Eye (anatomy); Growth factors; Immunoglobulins; Immunohistochemistry; Intervention; Mass spectrometry; Mass spectroscopy; Medical imaging; Occlusion; Permeability; Pigment epithelium-derived factor; Polypeptides; Proteins; proteome; Proteomes; Proteomics; Reproducibility; Retina; retinal vein occlusion; Saline water; Scientific imaging; Vascular endothelial growth factor; Veins & arteries; Western blotting; proteomics; aflibercept; retina; vascular endothelial growth factor; retinal vein occlusion; mass spectrometry; proteome
• ISSN: 1420-3049; 1420-3049
• DOI: 10.3390/molecules27113360

Aflibercept is a frequently used inhibitor of vascular endothelial growth factor (VEGF) in the treatment of macular edema following central retinal vein occlusion (CRVO). Retinal proteome changes following aflibercept intervention in CRVO remain largely unstudied. Studying proteomic changes of aflibercept intervention may generate a better understanding of mechanisms of action and uncover aspects related to the safety profile. In 10 Danish Landrace pigs, CRVO was induced in both eyes with an argon laser. Right eyes were treated with intravitreal aflibercept while left control eyes received isotonic saline water. Retinal samples were collected 15 days after induced CRVO. Proteomic analysis by tandem mass tag-based mass spectrometry identified a total of 21 proteins that were changed in content following aflibercept intervention. In retinas treated with aflibercept, high levels of aflibercept components were reached, including the VEGF receptor-1 and VEGF receptor-2 domains. Fold changes in the additional proteins ranged between 0.70 and 1.19. Aflibercept intervention resulted in a downregulation of pigment epithelium-derived factor (PEDF) (fold change = 0.84) and endoplasmin (fold change = 0.91). The changes were slight and could thereby not be confirmed with less precise immunohistochemistry and Western blotting. Our data suggest that aflibercept had a narrow mechanism of action in the CRVO model. This may be an important observation in cases when macular edema secondary to CRVO is resistant to aflibercept intervention.